Want to see AU:RHT full AI Analyst Report?
Top Page
Resonance Health Ltd
(Sydney:RHT)
Select Model
Select Model
Rating:65Neutral
Price Target:
AU$0.08
â–²(60.00% Upside)
Action:Reiterated
Date:10/28/26
The score is driven primarily by improving financial performance (profitability and cash flow rebounding in 2026 alongside strong revenue growth), tempered by volatility in results and higher leverage versus earlier years. Technicals are mixed with near-term weakness but a still-positive longer-term trend, while valuation (P/E ~23) and the lack of a dividend yield keep the overall score in the mid-range.
Positive Factors
Multi-year revenue growth
The multi-year revenue scale-up indicates broader commercial adoption of the company’s imaging software and related services. Continued expansion of the revenue base can support operating leverage, strengthen the platform’s market presence, and provide a larger foundation for future cash generation.
Negative Factors
Earnings volatility
The sharp movement between profit and loss shows that reported earnings have not yet demonstrated consistent stability. Such volatility makes future profitability harder to rely on, can complicate investment planning, and may constrain confidence in the durability of the latest recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year revenue growth
The multi-year revenue scale-up indicates broader commercial adoption of the company’s imaging software and related services. Continued expansion of the revenue base can support operating leverage, strengthen the platform’s market presence, and provide a larger foundation for future cash generation.
Read all positive factors
Resonance Health Ltd (RHT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$35.31M
Dividend YieldN/A
Average Volume (3M)736.23K
Price to Earnings (P/E)23.1
Beta (1Y)1.64
Revenue Growth42.25%
EPS GrowthN/A
CountryAU
Employees18
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)<0.01
Shares Outstanding477,120,240
10 Day Avg. Volume1,071,232
30 Day Avg. Volume736,228
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)1.87
Price to Sales (P/S)1.32
P/FCF Ratio7.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Resonance Health Ltd Business Overview & Revenue Model
Company Description
Resonance Health Limited is a global provider of healthcare technology and services, specializing in the design, development, and production of software-as-medical devices. The company serves markets across the Asia Pacific, Americas, Europe, Midd...
How the Company Makes Money
Resonance Health generates revenue primarily by commercialising its medical imaging software and related services. Key revenue streams include: (1) Software licensing and subscriptions: income from licensing its imaging-analysis software to hospit...
Resonance Health Ltd Financial Statement Overview
Summary
Income Statement
71
Positive
Balance Sheet
63
Positive
Cash Flow
68
Positive
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.75M | 11.07M | 8.59M | 4.40M | 3.83M |
| Gross Profit | 14.80M | 11.07M | 8.59M | 4.40M | 3.83M |
| EBITDA | 2.48M | -618.63K | -382.00K | -827.69K | -1.34M |
| Net Income | 1.51M | -1.73M | 169.30K | -780.00K | -1.14M |
Balance Sheet | |||||
| Total Assets | 18.74M | 17.89M | 20.28M | 10.98M | 11.69M |
| Cash, Cash Equivalents and Short-Term Investments | 4.85M | 2.98M | 6.85M | 6.36M | 6.78M |
| Total Debt | 3.81M | 3.80M | 3.70M | 272.94K | 268.22K |
| Total Liabilities | 7.63M | 8.50M | 9.35M | 1.05M | 995.58K |
| Stockholders Equity | 11.11M | 9.39M | 10.93M | 9.94M | 10.69M |
Cash Flow | |||||
| Free Cash Flow | 2.79M | 805.39K | 1.01M | -624.93K | -1.42M |
| Operating Cash Flow | 2.88M | 1.25M | 1.39M | -157.03K | -712.67K |
| Investing Cash Flow | -300.53K | -4.52M | -3.94M | -467.90K | -704.00K |
| Financing Cash Flow | -597.54K | -649.26K | 3.01M | -81.97K | -107.11K |
Resonance Health Ltd Technical Analysis
Neutral
0.05
Price Trends
0.07
Positive
0.06
Positive
0.05
Positive
Market Momentum
<0.01
Positive
45.89
Neutral
37.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:RHT, the sentiment is Neutral. The current price of 0.05 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.07, and below the 200-day MA of 0.05, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.89 is Neutral, neither overbought nor oversold. The STOCH value of 37.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:RHT.
Resonance Health Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$20.50B | 77.24 | 63.19% | 0.35% | 22.87% | 130.30% | |
65 Neutral | AU$35.31M | 23.13 | 13.72% | ― | 42.25% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$61.10M | -6.84 | -24.29% | ― | -17.35% | -47.29% | |
45 Neutral | AU$21.26M | -1.14 | -58.13% | ― | 2.08% | -195.31% | |
44 Neutral | AU$58.70M | -8.87 | -57.06% | ― | 603.32% | 10.57% | |
44 Neutral | AU$453.27M | -15.92 | -30.04% | ― | <0.01% | 2.08% |
* Healthcare Sector Average
AU:RHT
Resonance Health Ltd
0.07
0.02
51.02%
AU:PME
Pro Medicus Limited
196.20
-66.13
-25.21%
AU:M7T
Mach7 Technologies
0.26
-0.04
-13.33%
AU:BMT
Beamtree Holdings Ltd
0.07
-0.15
-67.27%
AU:SHG
Singular Health Group Ltd
0.18
-0.10
-36.84%
AU:AYA
Artrya Limited
2.77
-0.64
-18.77%
Resonance Health Ltd Corporate Events
Resonance Health Unveils Early MRI Liver Fibrosis Data and Plans Capital Raise
Oct 26, 2026
Resonance Health has presented preliminary data from its extended proof-of-concept clinical study for a non-invasive MRI liver fibrosis device. The investigational technology was assessed in 50 subjects across a broad spectrum of liver conditions,...
Resonance Health Plans Major Share Placement on ASX
Oct 26, 2026
Resonance Health Ltd has notified the ASX of a proposed issue of up to 83,333,319 ordinary fully paid shares. The securities are to be issued via a placement or similar structure, with a proposed issue date of 9 November 2026, subject to ASX proce...
Resonance Health’s MRI Fibrosis Tool Matches FibroScan, Targets $1.3bn Trial Market
Oct 26, 2026
Resonance Health has reported preliminary extended proof-of-concept results for its FibrosisAssessment MRI-based liver fibrosis software, showing diagnostic accuracy comparable to the widely used FibroScan ultrasound device for significant fibrosi...
Resonance Health Seeks ASX Trading Halt Ahead of Clinical Trial Update and Capital Raising
Oct 22, 2026
Resonance Health Ltd has requested a trading halt in its ordinary shares on the ASX, effective from the start of trading on 23 October 2026. The halt is designed to support the company’s compliance with continuous disclosure rules while it p...
Resonance Health Sets Date and Voting Details for 2026 AGM
Oct 20, 2026
Resonance Health Ltd has scheduled its 2026 Annual General Meeting for 19 November 2026 at the QV1 Building in Perth, Western Australia. The company will not mail physical copies of the Notice of Meeting and Explanatory Statement to shareholders w...
Resonance Health Sets Date to Reveal Key Trial Data on MRI Liver Fibrosis Device
Oct 19, 2026
Resonance Health Ltd, an Australian healthcare technology firm, provides non-invasive MRI-based Software-as-Medical Devices and imaging services that support clinicians and pharmaceutical companies worldwide. Its AI-driven products for liver and c...
Resonance Health Sets AGM Date and Board Nomination Deadline
Sep 29, 2026
Resonance Health Ltd has scheduled its next Annual General Meeting for 19 November 2026, with formal meeting materials to be circulated to shareholders and published via the ASX and the company’s investor website in due course. The company h...
Resonance Health Strikes Global Imaging Alliance with Image Analysis Group
Sep 16, 2026
Resonance Health has signed a Strategic Alliance and Master Services Agreement with London-based Image Analysis Group, integrating its quantitative MRI endpoints into IAG’s global imaging clinical research platform. The deal makes Resonance&...
Resonance Health Files 2026 Corporate Governance Statement with ASX
Aug 31, 2026
Resonance Health Limited has lodged its Appendix 4G and corporate governance statement with the ASX for the financial year ended 30 June 2026, confirming compliance with ASX Listing Rules on governance disclosure. The documents, approved by the bo...
Resonance Health Returns to Profit on Record Revenue and Strong Trial Pipeline
Aug 28, 2026
Resonance Health reported a 42% rise in full-year revenue to $15.8 million and returned to profitability with a $1.5 million net profit after tax for the year to 30 June 2026. Normalised EBITDA jumped 83% to $2.6 million at a 16% margin, with all ...
Resonance Health swings to profit on 42% revenue surge
Aug 27, 2026
Resonance Health Limited reported a strong turnaround for the year ended 30 June 2026, with revenues from ordinary activities rising 42% to $15.75 million and net profit after tax of $1.51 million, compared with a loss of $1.73 million in the prio...
Resonance Health to Host Investor Webinar on FY26 Results
Aug 19, 2026
Resonance Health will release its full-year financial results for the period to 30 June 2026 on or before 28 August 2026 via the ASX platform. The company’s chief executive officer and chief financial officer will then host a live, interacti...
Resonance Health Ends ASX Quarterly Cash Flow Reporting After Strong FY26 Performance
Aug 12, 2026
Resonance Health Ltd, an Australian healthcare technology firm, specialises in AI‑enabled, MRI‑based Software‑as‑Medical Devices used globally for quantitative assessments of liver and cardiac conditions. Its solutions supp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.